<DOC>
	<DOC>NCT02939391</DOC>
	<brief_summary>The primary objective is to evaluate the effect of KW-6356 on motor symptoms in Parkinson's disease and the primary endpoint is the change from baseline in the MDS-UPDRS part III score between KW-6356 and placebo in subjects with early Parkinson's disease in Japan.</brief_summary>
	<brief_title>A Study of KW-6356 in Subjects With Early Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Subject fulfills the UK Parkinson's Disease Society brain bank clinical diagnostic criteria Parkinson's disease patients in Stages 1 to 3 on the Modified Hoehn and Yahr Scale MDSUPDRS part III score of ≥ 15 Use of any CYP3A4/5related drugs within 2 weeks prior to enrollment. Use of any of the specified antiparkinsonian drugs and dopamine antagonists during the specified period. Treatment with levodopa/DCI at any time in the past for a period of 4 weeks or more. Neurosurgical operation for Parkinson's disease (stereotactic surgery, deep brain stimulation or gamma knife), or treatment by transcranial magnetic stimulation (TMS). Either of the following criteria consecutively at screening and enrollment; Resting Pulse &gt; 100 bpm Resting systolic blood pressure &gt; 140 mmHg, or diastolic blood pressure &gt; 90 mmHg Significant dementia or a MiniMental State Examination (MMSE) score of ≤ 23. Subject has a history or evidence of suicidal ideation (severity of 4 or 5) or any suicidal behavior based on an assessment with the ColumbiaSuicide Severity Rating Scale (CSSRS) at baseline. Anyone otherwise considered unsuitable for the study by the investigator or subinvestigator including those who are unable to communicate or to cooperate with the investigator or subinvestigator.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>